Bemarituzumab is a Monoclonal Antibody owned by Amgen, and is involved in 11 clinical trials, of which 5 were completed, 5 are ongoing, and 1 is planned.
Bemarituzumab is a fibroblast growth factor receptor 2b (FGFR2b) antagonist. The FGFR2b protein spans the cell membrane, so that one end of the protein remains inside the cell and the other end projects from the outer surface of the cell. This positioning allows the FGFR2b protein to interact with specific growth factors outside the cell and to receive signals that help the cell respond to its environment. FPA-144 binds to the FGFR2b protein and prevents the cascade of chemical reactions inside the cell that instruct the cell to undergo certain changes such as cell proliferation. This can result in antiproliferative and pro-apoptotic effects. The drug candidate also drive immune-based killing of tumor cells by antibody-dependent cell-mediated cytotoxicity (ADCC) and the recruitment of natural killer (NK) cells and T cells.
The revenue for Bemarituzumab is expected to reach a total of $7.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Bemarituzumab NPV Report.
Bemarituzumab [FPA-144] is under development for the treatment of solid tumors such as gastric cancer, gastroesophageal cancer, transitional cell carcinoma, lymphoma, bladder cancer, head and neck squamous cell carcinoma, lung adenocarcinoma, fallopian tube cancer, peritoneal cancer, esophageal squamous cell carcinoma, triple-negative breast cancer, pancreatic ductal adenocarcinoma, intrahepatic cholangiocarcinoma, colorectal adenocarcinoma, ovarian epithelial cell carcinoma, endometrial adenocarcinoma and cervical carcinoma. The drug candidate is administered through intravenous route. It is a humanized monoclonal antibody directed against a splice form of fibroblast growth factor receptor 2 (FGFR2). It is a targeted immunotherapy for FGFR2b-overexpressing tumors and designed to recruit tumor-killing NK cells into the tumor microenvironment. The drug candidate is developed based on Potelligent CHOK1SV technology. Potelligent CHOK1SV, combines the advantages of GS Gene Expression System with the glyco-engineered technology.
It was also under development for the treatment of breast cancer.
Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in six focused disease areas including cardiovascular diseases, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels such as print, television and online media. Amgen is headquartered in Thousand Oaks, California, the US.
The company reported revenues of (US Dollars) US$25,979 million for the fiscal year ended December 2021 (FY2021), an increase of 2.2% over FY2020. In FY2021, the company’s operating margin was 29.4%, compared to an operating margin of 35.9% in FY2020. In FY2021, the company recorded a net margin of 22.7%, compared to a net margin of 28.6% in FY2020. The company reported revenues of US$6,652 million for the third quarter ended September 2022, an increase of 0.9% over the previous quarter.
Quick View – Bemarituzumab
|Highest Development Stage|